Desferal (500 mg) 500mg/1Vial - 1Vial Injection (Deferoxamine) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes .

Public sector hospitals in India face a critical shortage of Desferal, a vital iron chelator, endangering thalassemia patients who cannot afford its high cost. India Today.

Novartis has assured that steps are being taken to ensure the adequate supply of Desferal, a drug crucial for treating iron overload in Thalassemia patients. The drug is manufactured exclusively ...

DESFERAL® (deferoxamine) is an injectable medicine indicated for the treatment of iron overload, which may occur for example following blood transfusions necessary for the treatment of beta ...

The deferoxamine patch offers a potentially significant improvement in the treatment of sickle cell patients patients with ulcers, but it faces a number of logistical and access challenges, some ...

Borgna-Pignatti C, Cappellini MD, DeStefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood . 2006;107:3733-3737 ...

Thalassemia patients are struggling to access Desferal, with many government hospitals lacking the drug despite its critical role in managing iron overload from blood transfusions. NEW DELHI ...

The hypothesis was tested that treatment with allopurinol, a xanthine oxidase inhibitor, or deferoxamine, a chelator of nonprotein-bound iron, preserved cerebral energy metabolism, attenuated ...

MITEM PHARMA Acquires Worldwide Rights to DESFERAL® (deferoxamine) With the Backing of TECHLIFE CAPITAL and MACSF. September 25, 2024 02:13 AM Eastern Daylight Time.

Novartis, however, denied any current shortage. “Currently, there is no shortage of Desferal in Delhi or elsewhere in India,” a spokesperson told Business Today.

MASSY, France, September 25, 2024--MITEM PHARMA, the pharmaceutical laboratory based in France and dedicated to Medicines of Major Therapeutic Interest (M.I.T.M.), is pleased to announce the ...

MITEM PHARMA, the pharmaceutical laboratory based in France and dedicated to Medicines of Major Therapeutic Interest (M.I.T.M.), is pleased to announce the worldwide acquisition of DESFERAL®, a major ...